Niealkoholowa stłuszczeniowa choroba wątroby - patogeneza i zasady postępowania

• Autorzy: Respondek W.

Warianty tytułu

EN

Non-alcoholoc fatty liver disease - pathogenesis and management

• Języki publikacji: PL

Abstrakty

PL

Niealkoholowa stłuszczeniowa choroba wątroby (non-alcoholic fatty liver disease, NAFLD) jest przewlekłą chorobą wątroby charakteryzującą się jej stłuszczeniem występującym u osoby niespożywającej alkoholu w istotnych ilościach (>10 g/dz). W miarę upływu czasu może ona prowadzić do niealkoholowego stłuszczeniowego zapalenia wątroby (non-alcoholic steatohepatitis, NASH), włóknienia miąższu wątroby, marskości, a także do raka wątrobokomórkowego. W krajach rozwiniętych NAFLD jest najczęstszą przyczyną przypadkowo stwierdzonej podwyższonej aktywności enzymów wątrobowych. Najważniejszym czynnikiem ryzyka rozwoju NAFLD jest otyłość brzuszna. Przez wielu autorów uznawana jest ona za wątrobową manifestację zespołu metabolicznego. Podstawą leczenia tego schorzenia jest modyfikacja stylu życia, oparta przede wszystkim na zmianie nawyków żywieniowych, zwiększeniu systematycznej aktywności fizycznej i redukcji masy ciała, zwłaszcza trzewnej tkanki tłuszczowej.

EN

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease which refers to the presence of hepatic steatosis without significant intake of alcohol. NAFLD can progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is currently the most common cause of incidental elevated serum liver enzyme activities in the developed world. The abdominal obesity is the most important risk factor for NAFLD. By many authors it is considered to be hepatic manifestation of metabolic syndrome. The treatment of NAFLD focuses on life-style modifications based on dietary habits changes, increasing physical activity and body weight reduction, especially reduction of the visceral fatty tissue.

Słowa kluczowe

PL

choroby czlowieka; zywienie czlowieka; styl zycia; niealkoholowa stluszczeniowa choroba watroby; stluszczenie watroby; watroba; patogeneza; trojglicerydy; leczenie

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2012
• Tom: 39
• Numer: 5-6
• Opis fizyczny: s.309-319,tab.,bibliogr.

Twórcy

autor

Respondek W.

• Zakład Dietetyki i Żywienia Szpitalnego, Instytut Żywności i Żywienia w Warszawie, ul.Powsińska 61/63, 02-903 Warszawa

Bibliografia

• 1. Szczepaniak L.S., Nurenberg P., Leonard D., et al.: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosisin the general population. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E462-E468.-
• 2. Adams L.A., Lindor K.D.: Nonalcoholic fatty liver disease. Ann. Epidemiol., 2007, 17, 863-869.-
• 3. Targher G.: Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular diseases: the plot thickens. Diabetic Medicine 2007, 24, 1-6.-
• 4. Kotronen A., Yki-Järvinen H.: Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 27-38.-
• 5. Scorletti E., Calder P.C., Byrne C.D: Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011, 40, 332-343.-
• 6. Targher G., Bertolini L., Padovano R., et al.: Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30, 1212-1218.-
• 7. de Alwis N.M.W., Day C.P.: Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol., 2008, 48, S104-S112.-
• 8. Ekstedt M., Franzen L.E., Mathiesen U.L., et al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44, 865-873.-
• 9. Keller J.S.: Trawienie i wchłanianie składników odżywczych w przewodzie pokarmowym. W: Podstawy fizjologii żywienia człowieka. SGGW, Warszawa, 2000.-
• 10. Brunzell J.D., Failor R.L.: Diagnosis and Treatment of Dyslipidemia. http://www.medscape.com/viewarticle/521683 (Access – 1.02.2013).
• 11. Krawczyk M., Bonfrate L., Portincasa P.: Nonalcoholic fatty liver disease. Best Practice Res. Clin. Gastroent. 2010, 24, 695-708.-
• 12. Myrda K., Rozentryt P., Nowak J., et al.: Tkanka tłuszczowa w niewydolności serca - wróg czy przyjaciel? Folia Cardiologica Excerpta 2010, 5, 234-241.-
• 13. National Institutes of Health: Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. Bethesda, Md.: National Institutes of Health, National Heart Lung and Blood Institute, 2001 (NIH publication no. 01-3670). Accessed online January 31, 2013, at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm.-
• 14. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org.-
• 15. Raszeja-Wyszomirska J., Ławniczak M., Marlicz W., i wsp.: Niealkoholowa stłuszczeniowa choroba wątroby - nowe spojrzenie. Pol. Merk. Lek., 2008, 144, 568-571.-
• 16. Ahima R.S.: Insulin resistance: cause or consequence of nonalcoholic steatoheptitis. Gastroenterology 2007, 132, 444-446.-
• 17. Greenfield V., Cheung O., Sanyal A.J.: Recent advances in nonalcoholic fatty liver disease. Curr. Opin. in Gastroenterol 2008, 24, 320-327.-
• 18. Jansen M.D.: Adipose tissue as an endocrine organ: implications of its distribution on free fatty acid metabolizm. European Heart Journal Supplements 2006, 8 (Supplement B), B13-B19.-
• 19. Diehl A.M., Li Z.P., Lin H.Z., Yang S.Q.: Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005, 54, 303-306.-
• 20. Das S.K., Balakrishnan V.: Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Ind. J. Clin. Biochem., 2011, 26: 202-209.-
• 21. Choi S., Diehl A.M.: Role of inflammation in nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol., 2005, 21, 702-707.-
• 22. Leclerq I.A., Farrell G.C., Schriemer R., et al.: Leptin is essential fort he hepatic fibrogenesis response to chronic liver injury. J. Hepatol., 2002, 27, 206-213.-
• 23. Tacikowski T., Dzieniszewski J., Ciok J., Godziemba-Maliszewska E.: Niealkoholowa choroba stłuszczeniowa wątroby. Gastroenterol. Pol., 2004, 11, 271-278.-
• 24. Kallwitz E.R., Kumar M., Aggarwal R., et al.: Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig. Dis. Sci., 2008, 53, 1358-1363.-
• 25. Reymer C., Kowdley K.V., Larson A., et al.: Prevalence and predictors of asymptomatoc liver disease in patients undergoing gastric bypass surgey. Arch. Surg., 2003, 138, 1240-1244.-
• 26. Chantal A.R.: Risk factors and mechanism of non-alcoholic steatohepatitis. Pathophysiology 2008, 15, 109-114.-
• 27. Stepanova M., Afendy M., Srishord M.: Sleep disorders in individuals with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 2012, 56, (Suppl. 2), S525.-
• 28. Musso G., Gambino R., Cassader M., Pagano G.: A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52, 79-104.-
• 29. De Luis D., Aller R., Izaola O., et al.: Effect of hypocaloric diet in transaminase in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance. Diabetes Res. Clin. Pract., 2008, 79, 74-78.-
• 30. Huang M., Greenson J., Chao C., et al.: One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol., 2005, 100, 1072-1081.-
• 31. Expert Panel on the Identification, Evaluation and Treatment of Overweight in Adults. Am. J. Clin. Nutr., 1998, 68, 899-91.-
• 32. McNear S., Harrisom S.A.: Review: Current status of therapy in nonalcoholic fatty liver disease. Ther. Adv. Gastroenterol., 2009, 2, 29-43.-
• 33. Ryan M., Abbasi F., Lamendola C., et al.: Serum alanine aminotransferase levels decrease further with carbohydrate than FAT restriction in insulin-resistnt adults. Diabetes Care 2007, 30, 1075-1080.-
• 34. Ouyang X., Cirillo P., Austin Y., et al.: Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J. Hepatol., 2008, 48, 993-999.
• 35. Spruss A., Bergheim I.: Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J. Nutr. Biochem., 2009, 20, 657-662.-
• 36. Abdelmalek M.F., Suzuki A., Guy C., et al.: Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51, 1961-1971.-
• 37. Kechagias S., Ernersson A., Dahlqvist O., et al.: Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subject. Gut 2008, 57, 649-654.-
• 38. Welch R.W., Kelly M.T., Gallagher A.M., et al.: The effects of inulin-type fructans on satiety and energy intake: human studies. AgroFood Industry Hi-Tech., 2008, 19, 4-6.-
• 39. Vrieze A., Holleman F., Zoetendal E.G., et al.: The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010, 53, 606-613.-
• 40. Cani P.D., Joly E., Horsmans Y., et al.: Oligofructose promotes satiety in healthy human: a pilot study. Eur. J. Clin. Nutr., 2006, 60, 567-572.-
• 41. Parnell J.A., Reimer R.A.: Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overwight and obese adult. Am. J. Clin. Nutr., 2009, 89, 1751-1759.-
• 42. Daubioul C., Horsman Y., Lambert P., et al.: Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of pilot study. Eur. J. Clin. Nutr., 2005, 59,723-726.-
• 43. Galisteo M., Duarte J., Zarzuelo A.: Effects of dietary fibers on disturbances clustered in the metabolic syndrome. J. Natr. Biochem., 2008, 19, 71-84.-
• 44. Esposito K., Pontillo A., Di Palo C., et al.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J. Am. Med. Assoc., 2003, 289: 1799-1804.-
• 45. Song Y.J., Sawamura M., Kieda K., et al.: Soluble dietary fibre improves insulin sensitivity by increasing muscle GLUT-4 content in stroke-prone spontaneusly hypertensive rats. Clin. Exp. Pharmacol. Physiol., 2000, 27, 41-45.-
• 46. Weickert M.O., Modlin M., Schofl C., et al.: Cereal fibre improves whole-body insulin sensitivity in overwight and obese women. Diabetes Care 2006, 29, 775-780.-
• 47. Spadaro L., Magliocco O., Spampinato D., et al.: Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and Liver Disease., 2008, 40, 194-199.-
• 48. Chalasani N., Younossi Z., Lavine J.E., et al.: The diagnosis and management of non-alcoholic fatty liver disease: Pracice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. Hepatology 2012, 55, 2005-2023.-
• 49. Meyer B.J.: Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? Prostaglandins, Leucotrienes Essential Fatty Acids 2011, 85, 275-80.-
• 50. Sanyal A.J., Chalasani N., Kowdley K.V., et al.: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med., 2010, 362, 1675-1685.-
• 51. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al.: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. J. Am. Med. Assoc. 2011, 305: 1659-1668.-
• 52. Miller E.R., Pastor-Barriuso R., Dala D., et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med., 2005, 142, 37-46.-
• 53. Berry D., Wathen J.K., Newell M.: Bayesian model averaging in metaanalysis: witamin E supplementation and mortality. Clin. Trias., 2009, 6, 28-41.-
• 54. Donnelly J., Blair S., Jakicic J. et al.: Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults. Med. Sci. Sports Exerc., 2009, 41, 459-471.